Abstract
Recent studies reported cardioprotective effects of erythropoietin (EPO) against ischemia–reperfusion (I/R) injury through activation of the reperfusion injury salvage kinase (RISK) pathway. As RISK has been reported to be impaired in diabetes and insulin resistance syndrome, we examined whether EPO-induced cardioprotection was maintained in rat models of type 1 diabetes and insulin resistance syndrome. Isolated hearts were obtained from three rat cohorts: healthy controls, streptozotocin (STZ)-induced diabetes, and high-fat diet (HFD)-induced insulin resistance syndrome. All hearts underwent 25 min ischemia and 30 min or 120 min reperfusion. They were assigned to receive either no intervention or a single dose of EPO at the onset of reperfusion. In hearts from healthy controls, EPO decreased infarct size (14.36 ± 0.60 and 36.22 ± 4.20% of left ventricle in EPO-treated and untreated hearts, respectively, p < 0.05) and increased phosphorylated forms of Akt, ERK1/2, and their downstream target GSK-3β. In hearts from STZ-induced diabetic rats, EPO did not decrease infarct size (32.05 ± 2.38 and 31.88 ± 1.87% in EPO-treated and untreated diabetic rat hearts, respectively, NS) nor did it increase phosphorylation of Akt, ERK1/2, and GSK-3β. In contrast, in hearts from HFD-induced insulin resistance rats, EPO decreased infarct size (18.66 ± 1.99 and 34.62 ± 3.41% in EPO-treated and untreated HFD rat hearts, respectively, p < 0.05) and increased phosphorylation of Akt, ERK1/2, and GSK-3β. Administration of GSK-3β inhibitor SB216763 was cardioprotective in healthy and diabetic hearts. STZ-induced diabetes abolished EPO-induced cardioprotection against I/R injury through a disruption of upstream signaling of GSK-3β. In conclusion, direct inhibition of GSK-3β may provide an alternative strategy to protect diabetic hearts against I/R injury.
Similar content being viewed by others
References
Amour J, Brzezinska AK, Jager Z, Sullivan C, Weihrauch D, Du J, Vladic N, Shi Y, Warltier DC, Pratt PF Jr, Kersten JR (2010) Hyperglycemia adversely modulates endothelial nitric oxide synthase during anesthetic preconditioning through tetrahydrobiopterin- and heat shock protein 90-mediated mechanisms. Anesthesiology 112:576–585
Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, Mocanu MM, Yellon DM (2008) Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 103:274–284
Bullard AJ, Govewalla P, Yellon DM (2005) Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 100:397–403
Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100:4802–4806
Ceylan-Isik A, Hunkar T, Asan E, Kaymaz F, Ari N, Soylemezoglu T, Renda N, Soncul H, Bali M, Karasu C (2007) Cod liver oil supplementation improves cardiovascular and metabolic abnormalities in streptozotocin diabetic rats. J Pharm Pharmacol 59:1629–1641
Dikow R, Wasserhess C, Zimmerer K, Kihm LP, Schaier M, Schwenger V, Hardt S, Tiefenbacher C, Katus H, Zeier M, Gross LM (2009) Effect of insulin and glucose infusion on myocardial infarction size in uraemic rats. Basic Res Cardiol 104:571–579
Dincer UD, Bidasee KR, Guner S, Tay A, Ozcelikay AT, Altan VM (2001) The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes 50:455–461
Ferdinandy P, Schulz R, Baxter GF (2007) Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59:418–458
Flamment M, Gueguen N, Wetterwald C, Simard G, Malthiery Y, Ducluzeau PH (2009) Effects of the cannabinoid CB1 antagonist, rimonabant, on hepatic mitochondrial function in rats fed a high fat diet. Am J Physiol Endocrinol Metab 297:E1162–E1170
Gross ER, Hsu AK, Gross GJ (2007) Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes 56:127–136
Guillard C, Chretien S, Pelus AS, Porteu F, Muller O, Mayeux P, Duprez V (2003) Activation of the mitogen-activated protein kinases Erk1/2 by erythropoietin receptor via a G(i)protein beta gamma-subunit-initiated pathway. J Biol Chem 278:11050–11056
Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E (2005) Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 19:1323–1325
Hausenloy DJ, Tsang A, Yellon DM (2005) The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15:69–75
Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61:448–460
Heusch G (2009) No RISK, no…cardioprotection? A critical perspective. Cardiovasc Res 84:173–175
Heusch G, Boengler K, Schulz R (2008) Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118:1915–1919
Joyeux-Faure M, Rossini E, Ribuot C, Faure P (2006) Fructose-fed rat hearts are protected against ischemia-reperfusion injury. Exp Biol Med (Maywood) 231:456–462
Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ (2004) Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113:1535–1549
Kaygisiz Z, Erkasap N, Yazihan N, Sayar K, Ataoglu H, Uyar R, Ikizler M (2006) Erythropoietin changes contractility, cAMP, and nitrite levels of isolated rat hearts. J Physiol Sci 56:247–251
Kehl F, Krolikowski JG, Mraovic B, Pagel PS, Warltier DC, Kersten JR (2002) Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction. Anesthesiology 96:183–188
Kersten JR, Montgomery MW, Ghassemi T, Gross ER, Toller WG, Pagel PS, Warltier DC (2001) Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol 280:H1744–H1750
Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC (2000) Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 278:H1218–H1224
Kim HS, Cho JE, Hwang KC, Shim YH, Lee JH, Kwak YL (2010) Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with anti-apoptotic pathways of survival. Eur J Pharmacol 628:132–139
Kristiansen SB, Lofgren B, Stottrup NB, Khatir D, Nielsen-Kudsk JE, Nielsen TT, Botker HE, Flyvbjerg A (2004) Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 47:1716–1721
Latifpour J, McNeill JH (1984) Cardiac autonomic receptors: effect of long-term experimental diabetes. J Pharmacol Exp Ther 230:242–249
Laviola L, Belsanti G, Davalli AM, Napoli R, Perrini S, Weir GC, Giorgino R, Giorgino F (2001) Effects of streptozocin diabetes and diabetes treatment by islet transplantation on in vivo insulin signaling in rat heart. Diabetes 50:2709–2720
Lim SY, Davidson SM, Yellon DM, Smith CC (2009) The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. Basic Res Cardiol 104:781–792
Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2004) Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 44:473–479
Liu Y, Thornton JD, Cohen MV, Downey JM, Schaffer SW (1993) Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction. Circulation 88:1273–1278
Maddaford TG, Russell JC, Pierce GN (1997) Postischemic cardiac performance in the insulin-resistant JCR:LA-cp rat. Am J Physiol 273:H1187–H1192
Miki T, Miura T, Hotta H, Tanno M, Yano T, Sato T, Terashima Y, Takada A, Ishikawa S, Shimamoto K (2009) ER stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-GSK-3{beta}-mediated suppression of mitochondrial permeability transition. Diabetes 58:2863–2872
Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349:1498–1504
Nishihara M, Miura T, Miki T, Tanno M, Yano T, Naitoh K, Ohori K, Hotta H, Terashima Y, Shimamoto K (2007) Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J Mol Cell Cardiol 43:564–570
Park SS, Zhao H, Mueller RA, Xu Z (2006) Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. J Mol Cell Cardiol 40:708–716
Paulson DJ (1997) The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res 34:104–112
Prunier F, Pfister O, Hadri L, Liang L, Del Monte F, Liao R, Hajjar RJ (2007) Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 292:H522–H529
Przyklenk K, Maynard M, Greiner DL, Whittaker P (2010) Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal. doi:10.1089/ars.2010.3343
Rafiee P, Shi Y, Su J, Pritchard KA Jr, Tweddell JS, Baker JE (2005) Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 100:187–197
Raphael J, Gozal Y, Navot N, Zuo Z (2010) Hyperglycemia inhibits anesthetic-induced postconditioning in the rabbit heart via modulation of phosphatidylinositol-3-kinase/Akt and endothelial nitric oxide synthase signaling. J Cardiovasc Pharmacol 55:348–357
Ravingerova T, Stetka R, Volkovova K, Pancza D, Dzurba A, Ziegelhoffer A, Styk J (2000) Acute diabetes modulates response to ischemia in isolated rat heart. Mol Cell Biochem 210:143–151
Riksen NP, Hausenloy DJ, Yellon DM (2008) Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 29:258–267
Shanmuganathan S, Hausenloy DJ, Duchen MR, Yellon DM (2005) Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. Am J Physiol Heart Circ Physiol 289:H237–H242
Sharma A, Singh M (2000) Possible mechanism of cardioprotective effect of ischaemic preconditioning in isolated rat heart. Pharmacol Res 41:635–640
Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K (2002) Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes 51:1110–1117
Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, Schulz R, Heusch G (2009) Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 104:15–18
Tamareille S, Ghaboura N, Treguer F, Khachman D, Croue A, Henrion D, Furber A, Prunier F (2009) Myocardial reperfusion injury management: erythropoietin compared with postconditioning. Am J Physiol Heart Circ Physiol 297:H2035–H2043
Tanaka K, Kehl F, Gu W, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR (2002) Isoflurane-induced preconditioning is attenuated by diabetes. Am J Physiol Heart Circ Physiol 282:H2018–H2023
Thim T, Bentzon JF, Kristiansen SB, Simonsen U, Andersen HL, Wassermann K, Falk E (2006) Size of myocardial infarction induced by ischaemia/reperfusion is unaltered in rats with metabolic syndrome. Clin Sci (Lond) 110:665–671
Tong H, Imahashi K, Steenbergen C, Murphy E (2002) Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res 90:377–379
Tosaki A, Engelman DT, Engelman RM, Das DK (1996) The evolution of diabetic response to ischemia/reperfusion and preconditioning in isolated working rat hearts. Cardiovasc Res 31:526–536
Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El-Sherif N (2003) Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 308:990–994
Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM (2005) Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 54:2360–2364
Wagner C, Kloeting I, Strasser RH, Weinbrenner C (2008) Cardioprotection by postconditioning is lost in WOKW rats with metabolic syndrome: role of glycogen synthase kinase 3beta. J Cardiovasc Pharmacol 52:430–437
Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO (2004) Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18:1031–1033
Wright JJ, Kim J, Buchanan J, Boudina S, Sena S, Bakirtzi K, Ilkun O, Theobald HA, Cooksey RC, Kandror KV, Abel ED (2009) Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc Res 82:351–360
Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121–1135
Acknowledgments
We would like to thank Pierre Legras and Jerome Roux from the animal facilities for taking care of the animals, and Robert Filmon (Service Commun d’Imageries et d’Analyses Microscopiques) for his technical assistance. S. Tamareille and N. Ghaboura were supported by a fellowship from the Conseil Général du Maine et Loire.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ghaboura, N., Tamareille, S., Ducluzeau, PH. et al. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling. Basic Res Cardiol 106, 147–162 (2011). https://doi.org/10.1007/s00395-010-0130-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00395-010-0130-3